Spain has published a draft royal decree on the public financing and price-setting of medicines in the National Health System, moving the current reform sequence from health technology assessment into pricing, reimbursement and post-launch review. The Ministry of Health (Ministerio de Sanidad, MS) opened the consultation on 19 June, with comments due by 10 July.
The draft follows Royal Decree 415/2026 of 27 May, which established Spain’s national health technology assessment framework. The new text sets out how the results of national HTA, EU Joint Clinical Assessment reports and other technical material may feed into later financing and price decisions.
The draft would give a formal role to a technical financing and price report, followed by an ‘adoption report’. That report would take account of HTA material, the administrative file and other evidence relevant to public financing criteria. It could address the medicine’s place against available alternatives, conditions of use in the National Health System, uncertainty management and other issues relevant to price, financing or utilisation. The report would be technical and non-binding, but would form part of the material sent to the Interministerial Commission on Medicine Prices (Comisión Interministerial de Precios, CIMP).
The CIMP would decide on inclusion in public financing, maximum financed ex-factory price and applicable conditions. The draft also gives clearer regulatory form to access and financing agreements. These could include economic arrangements, outcome-based elements, volume or use controls, evidence-generation commitments and other mechanisms for managing clinical, financial or utilisation uncertainty.
The draft distinguishes conditional and provisional financing. Conditional financing would be linked to evidence-generation or uncertainty-reduction obligations. Provisional financing would allow temporary access while further information is completed before a definitive price and financing decision. Both routes would normally be limited to two years, with a possible one-year extension.
The draft also treats financing as a revisable status. Agreements could be reviewed when evidence, budget impact or conditions of use change, while special prescribing or dispensing restrictions would be reassessed at least every three years. The Financing Nomenclator would become the reference system for financing, dispensing, invoicing and payment, including financed indications, prices, special conditions and restrictions.
After the consultation closes on 10 July, the MS will need to review submissions, finalise the remaining reports and obtain the required advisory opinions before the text can go to the Council of Ministers. Approval and publication in the Boletín Oficial del Estado in late 2026 would be plausible if the process is not delayed, with entry into force 20 days after publication. A more contested consultation could push adoption into early 2027.
If adopted, the decree would make Spain’s pricing and reimbursement process more explicit, but also more dependent on structured evidence management after launch. The practical effect will depend on how often CIMP uses conditional financing, confidential agreements and reassessment to adjust price or funded use after the initial decision.
Source: Ministry of Health, Spain
Links:
Audiencia e información pública sobre el proyecto de Real Decreto por el que se regula el procedimiento de financiación y fijación de precios de los medicamentos en el Sistema Nacional de Salud (Public hearing and information on the draft Royal Decree regulating the procedure for financing and setting prices for medicines in the National Health System)
Proyecto de Real Decreto por el que se regula el procedimiento de financiación y fijación de precios de los medicamentos en el Sistema Nacional de Salud (Draft Royal Decree regulating the procedure for financing and setting prices for medicines in the National Health System)
Date: 19 June 2026
